title: [CPT-11 hepatic arterial injection plus oral UFT administration for liver metastasis of rectal cancer--report of two cases].
abstract: The first patient was a 51-year-old male who had 5-fluorouracil-resistant recurrent rectal cancer with multiple liver metastases. He was given our new combination chemotherapy consisting of hepatic arterial injection of CPT-11 (20 mg/body) on day 1 and day 2 and oral administration of UFT (300 mg/day) on days 3 to 6 of a 7 day cycle starting in January 2001. Six weeks after the beginning of chemotherapy, the liver metastatic lesions were reduced. He is now living with outpatient treatment. The second patient was a 76-year-old male who had initial recurrent rectal cancer with multiple liver metastases. Thirty-two weeks after the same chemotherapy, the metastatic lesions had completely disappeared. Twelve months have passed since this chemotherapy, and we have not found any recurrent tumor. While significant antitumor effects were observed, there were few adverse events in either patient. These results suggest that combined chemotherapy of CPT-11 by hepatic arterial injection and oral administration of UFT is an effective treatment for liver metastases of rectal cancer.
authors.affiliation: First Dept. of Surgery, Nagasaki University School of Medicine.
authors.forename: Terumitsu
authors.initials: T
authors.lastname: Sawai
authors.forename: Takashi
authors.initials: T
authors.lastname: Tsuji
authors.forename: Hideki
authors.initials: H
authors.lastname: Yamashita
authors.forename: Shigekazu
authors.initials: S
authors.lastname: Hidaka
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Fukuoka
authors.forename: Shinichi
authors.initials: S
authors.lastname: Shibasaki
authors.forename: Kenji
authors.initials: K
authors.lastname: Tanaka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nanashima
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Toru
authors.initials: T
authors.lastname: Yasutake
authors.forename: Toru
authors.initials: T
authors.lastname: Nakagoe
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Ayabe
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006499:Hepatic Artery; D006801:Humans; D007269:Injections, Intra-Arterial; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; D000077146:Irinotecan; D002166:Camptothecin